Metro International Biotech, LLC
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
0
Ending by 2030
Apr 2036
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 2 fees due Feb 27, 2027
- 1 fee due Apr 17, 2027The maintenance fee for Crystalline solids of nicotinic acid mononucleotide and esters thereof and methods of making and use (US 11,787,830) comes due Apr 17, 2027. Unpaid by Oct 18, 2027, it lapses early.
- 2 fees due Jul 23, 2027
- 1 fee due Aug 4, 2027The maintenance fee for Nicotinamide Mononucleotide Derivatives and Their Uses (US 10,548,913) comes due Aug 4, 2027. Unpaid by Feb 4, 2028, it lapses early.
- 2 fees due Sep 26 to 30, 2027 · next Sep 26
- 3 fees due Oct 9 to 16, 2027 · next Oct 9
Recent changes
- 1 of the patents on this record was granted since Aug 23, 2026
- Oct 20 US 12,767,684 Compounds and Compositions for Differential Modulation of Nicotinamide Adenine Dinucleotide
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 10,603,334 | Targeting NAD+ to treat chemotherapy and radiotherapy induced cognitive impairment, neuropathies and inactivity In force · USPTO record | In force | USPTO record | |
| US 11,389,469 | Targeting NAD+ to treat chemotherapy and radiotherapy induced cognitive impairment, neuropathies and inactivity In force · USPTO record | In force | USPTO record | |
| US 9,855,289 | Nicotinamide Mononucleotide Derivatives and Their Uses In force · Medium confidence | In force | Medium confidence | |
| US 9,919,003 | Nicotinamide Mononucleotide Derivatives and Their Uses In force · High confidence | In force | High confidence | |
| US 10,548,913 | Nicotinamide Mononucleotide Derivatives and Their Uses In force · Low confidence | In force | Low confidence | |
| US 11,464,796 | Nicotinamide Mononucleotide Derivatives and Their Uses In force · Low confidence | In force | Low confidence | |
| US 11,878,027 | Nicotinamide Mononucleotide Derivatives and Their Uses In force · Low confidence | In force | Low confidence | |
| US 12,485,135 | Nicotinamide Mononucleotide Derivatives and Their Uses In force · Low confidence | In force | Low confidence | |
| US 10,233,208 | Crystal Forms of Beta-Nicotinamide Mononucleotide In force · High confidence | In force | High confidence | |
| US 10,392,415 | CRYSTAL FORMS OF b-NICOTINAMIDE MONONUCLEOTIDE In force · High confidence | In force | High confidence |
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
1 pending · 1 abandoned · 1 no status recorded